The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Diabetic Retinopathy

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Diabetic Retinopathy


Psychiatry related information on Diabetic Retinopathy


High impact information on Diabetic Retinopathy

  • To determine whether two insulin-like growth factors (IGF I and IGF II) influence the course of diabetic retinopathy, we measured the concentrations of these factors in 80 adult patients with diabetes and in 62 control subjects [7].
  • Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy [8].
  • In retinas of diabetic animals, benfotiamine treatment inhibited these three pathways and NF-kappaB activation by activating transketolase, and also prevented experimental diabetic retinopathy [8].
  • In humans, vitreal stromal cell-derived factor-1 (SDF-1) concentration increases as proliferative diabetic retinopathy progresses [9].
  • IGF-1 has been associated with the pathogenesis of diabetic retinopathy, although its role is not fully understood [10].

Chemical compound and disease context of Diabetic Retinopathy


Biological context of Diabetic Retinopathy


Anatomical context of Diabetic Retinopathy


Gene context of Diabetic Retinopathy


Analytical, diagnostic and therapeutic context of Diabetic Retinopathy


  1. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. Aiello, L.P., Avery, R.L., Arrigg, P.G., Keyt, B.A., Jampel, H.D., Shah, S.T., Pasquale, L.R., Thieme, H., Iwamoto, M.A., Park, J.E. N. Engl. J. Med. (1994) [Pubmed]
  2. Vascular endothelial growth factor: basic science and clinical progress. Ferrara, N. Endocr. Rev. (2004) [Pubmed]
  3. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Klein, R., Klein, B.E., Moss, S.E. Ann. Intern. Med. (1996) [Pubmed]
  4. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Cherrington, J.M., Strawn, L.M., Shawver, L.K. Adv. Cancer Res. (2000) [Pubmed]
  5. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Miyamoto, K., Khosrof, S., Bursell, S.E., Rohan, R., Murata, T., Clermont, A.C., Aiello, L.P., Ogura, Y., Adamis, A.P. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  6. Disordered eating behavior and microvascular complications in young women with insulin-dependent diabetes mellitus. Rydall, A.C., Rodin, G.M., Olmsted, M.P., Devenyi, R.G., Daneman, D. N. Engl. J. Med. (1997) [Pubmed]
  7. Insulin-like growth factors. Studies in diabetics with and without retinopathy. Merimee, T.J., Zapf, J., Froesch, E.R. N. Engl. J. Med. (1983) [Pubmed]
  8. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Hammes, H.P., Du, X., Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., Lin, J., Bierhaus, A., Nawroth, P., Hannak, D., Neumaier, M., Bergfeld, R., Giardino, I., Brownlee, M. Nat. Med. (2003) [Pubmed]
  9. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. Butler, J.M., Guthrie, S.M., Koc, M., Afzal, A., Caballero, S., Brooks, H.L., Mames, R.N., Segal, M.S., Grant, M.B., Scott, E.W. J. Clin. Invest. (2005) [Pubmed]
  10. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. Ruberte, J., Ayuso, E., Navarro, M., Carretero, A., Nacher, V., Haurigot, V., George, M., Llombart, C., Casellas, A., Costa, C., Bosch, A., Bosch, F. J. Clin. Invest. (2004) [Pubmed]
  11. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. McCance, D.R., Dyer, D.G., Dunn, J.A., Bailie, K.E., Thorpe, S.R., Baynes, J.W., Lyons, T.J. J. Clin. Invest. (1993) [Pubmed]
  12. Fluorescein leakage: First sign of juvenile diabetic retinopathy. Dorchy, H., Toussaint, D. Lancet (1978) [Pubmed]
  13. Long-term blood glucose control and diabetic retinopathy. Finotti, P., Piccoli, A. Lancet (1990) [Pubmed]
  14. Angiotensin II, VEGF, and diabetic retinopathy. Stoschitzky, K. Lancet (1998) [Pubmed]
  15. Defective homocysteine metabolism as a risk factor for diabetic retinopathy. Neugebauer, S., Baba, T., Kurokawa, K., Watanabe, T. Lancet (1997) [Pubmed]
  16. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Liu, H., Ren, J.G., Cooper, W.L., Hawkins, C.E., Cowan, M.R., Tong, P.Y. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  17. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Hammes, H.P., Martin, S., Federlin, K., Geisen, K., Brownlee, M. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  18. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. Lambert, V., Munaut, C., Noël, A., Frankenne, F., Bajou, K., Gerard, R., Carmeliet, P., Defresne, M.P., Foidart, J.M., Rakic, J.M. FASEB J. (2001) [Pubmed]
  19. An (A-C)n dinucleotide repeat polymorphic marker at the 5' end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Ko, B.C., Lam, K.S., Wat, N.M., Chung, S.S. Diabetes (1995) [Pubmed]
  20. Protein kinase C beta2-dependent phosphorylation of core 2 GlcNAc-T promotes leukocyte-endothelial cell adhesion: a mechanism underlying capillary occlusion in diabetic retinopathy. Chibber, R., Ben-Mahmud, B.M., Mann, G.E., Zhang, J.J., Kohner, E.M. Diabetes (2003) [Pubmed]
  21. An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. Siemeister, G., Schirner, M., Reusch, P., Barleon, B., Marmé, D., Martiny-Baron, G. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  22. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Hammes, H.P., Lin, J., Wagner, P., Feng, Y., Vom Hagen, F., Krzizok, T., Renner, O., Breier, G., Brownlee, M., Deutsch, U. Diabetes (2004) [Pubmed]
  23. Aldose reductase expression in human diabetic retina and retinal pigment epithelium. Vinores, S.A., Campochiaro, P.A., Williams, E.H., May, E.E., Green, W.R., Sorenson, R.L. Diabetes (1988) [Pubmed]
  24. Activity of the glycosylating enzyme, core 2 GlcNAc (beta1,6) transferase, is higher in polymorphonuclear leukocytes from diabetic patients compared with age-matched control subjects: relevance to capillary occlusion in diabetic retinopathy. Chibber, R., Ben-Mahmud, B.M., Coppini, D., Christ, E., Kohner, E.M. Diabetes (2000) [Pubmed]
  25. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. Meyer-Schwickerath, R., Pfeiffer, A., Blum, W.F., Freyberger, H., Klein, M., Lösche, C., Röllmann, R., Schatz, H. J. Clin. Invest. (1993) [Pubmed]
  26. Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study. Burgos, R., Mateo, C., Cantón, A., Hernández, C., Mesa, J., Simó, R. Diabetes Care (2000) [Pubmed]
  27. Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-neuropeptide Y. Kallio, J., Pesonen, U., Jaakkola, U., Karvonen, M.K., Helenius, H., Koulu, M. J. Clin. Endocrinol. Metab. (2003) [Pubmed]
  28. No association between the MTHFR gene polymorphism and diabetic retinopathy in type 2 diabetic patients without overt nephropathy. Yoshioka, K., Yoshida, T., Takakura, Y., Kogure, A., Umekawa, T., Toda, H., Yoshikawa, T. Diabetes Care (2003) [Pubmed]
  29. An igf-I gene polymorphism modifies the risk of diabetic retinopathy. Rietveld, I., Ikram, M.K., Vingerling, J.R., Hofman, A., Pols, H.A., Lamberts, S.W., de Jong, P.T., van Duijn, C.M., Janssen, J.A. Diabetes (2006) [Pubmed]
  30. Genetic marker associations with proliferative retinopathy in persons diagnosed with diabetes before 30 yr of age. Cruickshanks, K.J., Vadheim, C.M., Moss, S.E., Roth, M.P., Riley, W.J., Maclaren, N.K., Langfield, D., Sparkes, R.S., Klein, R., Rotter, J.I. Diabetes (1992) [Pubmed]
  31. Risk of early-onset proliferative retinopathy in IDDM is closely related to cardiovascular autonomic neuropathy. Krolewski, A.S., Barzilay, J., Warram, J.H., Martin, B.C., Pfeifer, M., Rand, L.I. Diabetes (1992) [Pubmed]
  32. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Spranger, J., Osterhoff, M., Reimann, M., Möhlig, M., Ristow, M., Francis, M.K., Cristofalo, V., Hammes, H.P., Smith, G., Boulton, M., Pfeiffer, A.F. Diabetes (2001) [Pubmed]
  33. Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: association with retinal photocoagulation. Spranger, J., Hammes, H.P., Preissner, K.T., Schatz, H., Pfeiffer, A.F. Diabetologia (2000) [Pubmed]
  34. Glycation products and the pathogenesis of diabetic complications. Brownlee, M. Diabetes Care (1992) [Pubmed]
WikiGenes - Universities